Drug Trial Radar · NCT01768286
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection
Last checked: Nov 19, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
441
Actual
Start
Jan 2013
Primary completion
Nov 2013
Study completion Feb 2014
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jan 15, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir fixed dose combination (FDC) with or without ribavirin (RBV) administered for 12 or 24 weeks in treatment-experienced subjects with chronic genotype 1 hepatitis C virus (HCV) infection.
Conditions
- Chronic Hepatitis C Virus
Interventions
LDV/SOFDrug
Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
RBVDrug
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Time frame: Posttreatment Week 12
- Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study DrugTime frame: Up to 24 weeks
Locations
53 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Palo Alto, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Aurora, Colorado
Site not named
Englewood, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Atlanta, Georgia
Site not named
Marietta, Georgia
Site not named
Chicago, Illinois
Site not named
Indianapolis, Indiana
Site not named
Bowling Green, Kentucky
Site not named
Baton Rouge, Louisiana
Site not named
Baltimore, Maryland
Site not named
Lutherville, Maryland
Site not named
Boston, Massachusetts
Site not named
Springfield, Massachusetts
Site not named
Detroit, Michigan
Site not named
Rochester, Minnesota
Site not named
Saint Louis, Minnesota
Site not named
Saint Paul, Minnesota
Site not named
Kansas City, Missouri
Site not named
Berlin, New Jersey
Site not named
Hillsborough, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Santa Fe, New Mexico
Site not named
Binghamton, New York
Site not named
Manhasset, New York
Site not named
New York, New York
Site not named
Asheville, North Carolina
Site not named
Charlotte, North Carolina
Site not named
Durham, North Carolina
Site not named
Fayetteville, North Carolina
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.